Product Details   

   Product P i c t u r es   

  Product Introduction  

Cagrilintide Chemical Product Introduction

      Cagrilintide, a synthetic peptide with the molecular formula \(C_{194}H_{312}N_{54}O_{59}S_{2}\), represents a significant advancement in the field of metabolic disorder treatment.

      Structurally, Cagrilintide is engineered based on the human amylin (h - amylin) backbone. Its unique design, incorporating elements inspired by calcitonin, endows it with enhanced pharmacological properties. Unlike native amylin, which has a short half - life due to rapid degradation, Cagrilintide's acylation modification significantly extends its duration of action, allowing for less frequent dosing.

      The primary function of Cagrilintide lies in its ability to regulate metabolism effectively. It exerts multiple beneficial effects: by binding to AMYRs in the central nervous system, it reduces food intake and delays gastric emptying, thus promoting satiety and decreasing calorie consumption. Moreover, it modulates glucose metabolism, contributing to improved glycemic control. In pre - clinical animal studies, there is a notable decrease in food intake and body weight, validating its potential as an anti - obesity agent.

      In clinical trials, Cagrilintide has demonstrated promising results. In a Phase 2 dose - finding trial involving individuals with overweight or obesity, along with comorbidities such as hypertension or dyslipidaemia (but without type 2 diabetes), participants treated with Cagrilintide 2.4 mg, in combination with diet and exercise, achieved a remarkable 10% bodyweight reduction after 26 weeks, compared to only 3% in the placebo group. Additionally, ongoing research explores its combination with other drugs, such as the GLP - 1 agonist semaglutide. Preliminary data from combined treatment trials suggest synergistic effects, enabling more substantial and sustained weight loss in patients with obesity.

      Looking ahead, Cagrilintide holds great market potential. With the global prevalence of obesity and related metabolic disorders on the rise, there is an urgent need for effective therapeutic solutions. If successfully approved for market release, Cagrilintide could offer a new treatment option, either as a monotherapy or in combination with other drugs, potentially revolutionizing the management of obesity and associated health conditions. However, continued research and larger - scale clinical trials are essential to fully evaluate its long - term safety and efficacy profiles.

  Our Advantages  

  Packing

  Production Equipment  

  Company Profile   

  Trans porta tion Mo des  

P a y m e n t M o d e s